| scholarly article | Q13442814 |
| P50 | author | Tsuyoshi Yokoi | Q61658900 |
| P2093 | author name string | Miki Nakajima | |
| Yuki Tsuchiya | |||
| Shingo Takagi | |||
| Takao Taniya | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| P304 | page(s) | 9090-9098 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | MicroRNA regulates the expression of human cytochrome P450 1B1 | |
| P478 | volume | 66 |
| Q28117980 | A Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary Hypertension |
| Q34974334 | A role of miR-27 in the regulation of adipogenesis |
| Q33870658 | A systematic analysis of the skeletal muscle miRNA transcriptome of chicken varieties with divergent skeletal muscle growth identifies novel miRNAs and differentially expressed miRNAs |
| Q38289096 | A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer |
| Q37590000 | ABCC4 is regulated by microRNA-124a and microRNA-506 |
| Q37328429 | Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value |
| Q90739533 | An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS/STING Pathway in Pan-Cancer |
| Q21245772 | An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells |
| Q64900567 | Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. |
| Q27694164 | Breast cancer epigenetics: from DNA methylation to microRNAs |
| Q34590182 | Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells |
| Q36299728 | CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis |
| Q48232008 | CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder? |
| Q36459804 | CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. |
| Q97073424 | CYP1B1 gene: Implications in glaucoma and cancer |
| Q30440774 | CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma |
| Q53239841 | CYP1B1 mRNA inducibility due to benzo(a)pyrene is modified by the CYP1B1 L432V gene polymorphism. |
| Q92512924 | CYP1B1: A key regulator of redox homeostasis |
| Q37691006 | Chemoprevention of Rat Mammary Carcinogenesis by Apiaceae Spices |
| Q50198453 | Chorioamnionitis Induces a Specific Signature of Placental ABC Transporters Associated with an Increase of miR-331-5p in the Human Preterm Placenta. |
| Q37378012 | Current molecular diagnostics of breast cancer and the potential incorporation of microRNA |
| Q92190037 | Current trends in drug metabolism and pharmacokinetics |
| Q36960346 | Cyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substrates |
| Q33403734 | Data-driven methods to discover molecular determinants of serious adverse drug events |
| Q37139536 | Effective classification of microRNA precursors using feature mining and AdaBoost algorithms |
| Q36317177 | Effects of short-term exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on microRNA expression in zebrafish embryos |
| Q56689508 | Epigenetic Changes in Gene Expression for Drug-Metabolizing Enzymes and Transporters |
| Q37551896 | Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein |
| Q36237931 | Epigenetic regulation of drug metabolism and transport |
| Q38042440 | Epigenetic-dependent regulation of drug transport and metabolism: an update |
| Q36213062 | Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy. |
| Q36089079 | Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium |
| Q37250659 | Estrogen Regulation of MicroRNA Expression |
| Q28551028 | Expression Profile of Genes Related to Drug Metabolism in Human Brain Tumors |
| Q39255340 | Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1. |
| Q28478044 | Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors |
| Q38102553 | Friend or foe: the role of microRNA in chemotherapy resistance |
| Q34501025 | Genetic factors affecting drug disposition in Asian cancer patients. |
| Q34879842 | Genetic polymorphisms in miRNAs targeting the estrogen receptor and their effect on breast cancer risk. |
| Q33708471 | Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance |
| Q33497904 | Highly dynamic and sex-specific expression of microRNAs during early ES cell differentiation |
| Q36174736 | Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver |
| Q37344798 | Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells. |
| Q38634986 | Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine |
| Q40076710 | Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. |
| Q33735914 | Implications of genomic signatures in the differential vulnerability to fetal alcohol exposure in C57BL/6 and DBA/2 mice |
| Q52407682 | In Vitro Validation of miRNA-Mediated Gene Expression Linked to Drug Metabolism. |
| Q35846889 | In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression |
| Q35020657 | In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes |
| Q37193081 | Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223. |
| Q28477824 | Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment |
| Q34687041 | Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. |
| Q42252090 | Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. |
| Q42733696 | Involvement of microRNAs in dioxin-induced liver damage in the mouse. |
| Q28077589 | Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration |
| Q35781414 | Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. |
| Q90622246 | MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer |
| Q35791401 | MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells |
| Q28079075 | MiRNAs and miRNA Polymorphisms Modify Drug Response |
| Q37764166 | Micro-RNAs and breast cancer |
| Q36618667 | MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy |
| Q54944098 | MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management. |
| Q35171243 | MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. |
| Q38841918 | MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. |
| Q38701992 | MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation |
| Q38572337 | MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. |
| Q34987861 | MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines |
| Q36020910 | MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma |
| Q37199087 | MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells |
| Q38748118 | MicroRNAs and Cancer Drug Resistance |
| Q37736453 | MicroRNAs and pharmacogenomics |
| Q38235604 | MicroRNAs as key regulators of xenobiotic biotransformation and drug response. |
| Q58923813 | MicroRNAs in Cancer Drug Resistance and Drug Sensitivity |
| Q26781801 | MicroRNAs in Drug-induced Liver Injury |
| Q28081081 | MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential |
| Q30437444 | MicroRNAs in cancer |
| Q37402750 | MicroRNAs regulate CYP3A4 expression via direct and indirect targeting |
| Q37607478 | MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers. |
| Q35673637 | MicroRNAs: short non-coding players in cancer chemoresistance. |
| Q38187190 | MicroRNAs: the fine modulators of liver development and function |
| Q34499082 | Microarray-based analysis of microRNA expression in breast cancer stem cells |
| Q47141339 | Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells |
| Q28681868 | Modulation of the rat hepatic cytochrome P4501A subfamily using biotin supplementation |
| Q39400414 | Molecular and clinical attributes of uterine leiomyomas. |
| Q37613529 | Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment |
| Q34025838 | Molecular targets of epigenetic regulation and effectors of environmental influences |
| Q47631571 | Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans |
| Q55403266 | Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. |
| Q90179100 | Noncoding microRNAs: small RNAs play a big role in regulation of ADME? |
| Q36475190 | Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects |
| Q34912607 | Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts |
| Q46137385 | Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation |
| Q90740955 | Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers |
| Q38210476 | Personalized medicine and type 2 diabetes: lesson from epigenetics. |
| Q39012550 | Pharmacoepigenetics: an element of personalized therapy? |
| Q37401062 | Pharmacoepigenetics: its role in interindividual differences in drug response |
| Q36424755 | Pharmacogene regulatory elements: from discovery to applications |
| Q38100731 | Pharmacogenomics can improve antipsychotic treatment in schizophrenia |
| Q33993320 | Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective |
| Q37878207 | Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs |
| Q51552991 | Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. |
| Q41134824 | Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment |
| Q35578546 | Population differences in microRNA expression and biological implications |
| Q46759040 | Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. |
| Q37193085 | Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport |
| Q34425208 | Prenatal exposure to TCDD triggers significant modulation of microRNA expression profile in the thymus that affects consequent gene expression |
| Q44321577 | Profiling of differentially expressed microRNAs in premature ovarian failure in an animal model |
| Q34360047 | Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells |
| Q36930476 | Reducing Hepatocyte Injury and Necrosis in Response to Paracetamol Using Noncoding RNAs |
| Q37603906 | Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p |
| Q49668137 | Regulation of UGT1A expression by miR-298 in human livers from the Han Chinese population and in human cell lines |
| Q37259128 | Regulation of breast cancer and bone metastasis by microRNAs |
| Q35826285 | Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. |
| Q91876482 | Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis |
| Q39089977 | Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. |
| Q37193112 | Regulation of microRNA expression by rifampin in human hepatocytes |
| Q37587311 | Regulation of multidrug resistance by microRNAs in anti-cancer therapy |
| Q34994708 | Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis |
| Q33387675 | Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology |
| Q33850064 | Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators |
| Q37454657 | Review of MicroRNA Deregulation in Oral Cancer. Part I. |
| Q33418586 | Role of 3'UTRs in the translation of mRNAs regulated by oncogenic eIF4E--a computational inference |
| Q34571026 | Role of deregulated microRNAs in breast cancer progression using FFPE tissue |
| Q39059921 | Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. |
| Q39515361 | Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma |
| Q37823851 | Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s |
| Q37371739 | ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation |
| Q90568559 | Single-nucleotide polymorphisms and mRNA expression of CYP1B1 influence treatment response in triple negative breast cancer patients undergoing chemotherapy |
| Q37193077 | Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1 |
| Q36588312 | Species difference in the regulation of cytochrome P450 2S1: lack of induction in rats by the aryl hydrocarbon receptor agonist PCB126 |
| Q36919395 | Strain differences in cytochrome P450 mRNA and protein expression, and enzymatic activity among Sprague Dawley, Wistar, Brown Norway and Dark Agouti rats |
| Q35109229 | Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. |
| Q60950082 | TCDD Toxicity Mediated by Epigenetic Mechanisms |
| Q52315457 | Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. |
| Q48172048 | The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation |
| Q92811652 | The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology |
| Q37617645 | The effect of microRNAs in the regulation of human CYP3A4: a systematic study using a mathematical model |
| Q26822987 | The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs |
| Q35599477 | The emerging role of microRNAs in drug responses |
| Q38128592 | The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications. |
| Q37262636 | The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma |
| Q47116057 | The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. |
| Q36925256 | The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin |
| Q34540405 | The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells |
| Q37736451 | The past, present and future of pharmacoepigenomics |
| Q38937221 | The pharmacoepigenetics of drug metabolism and transport in breast cancer: review of the literature and in silico analysis |
| Q64265004 | The protective role of rs56103835 against breast cancer onset in the Iranian population |
| Q64237748 | The role and mechanisms of action of microRNAs in cancer drug resistance |
| Q47701015 | Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease |
| Q37895810 | Toxicological implications of modulation of gene expression by microRNAs. |
| Q33455600 | Transcriptome-wide prediction of miRNA targets in human and mouse using FASTH. |
| Q35291824 | miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. |
| Q34771896 | miRNA Biomarkers in Breast Cancer Detection and Management |
| Q98464606 | miRNA-based biomarkers, therapies, and resistance in Cancer |
| Q34070399 | miRNAs: effectors of environmental influences on gene expression and disease |
| Q57106025 | microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy |
| Q35063942 | microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450 |
| Q37760459 | microRNAs and EMT in mammary cells and breast cancer. |
| Q26778918 | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment |
Search more.